Tandem Diabetes Care, Inc.
TNDM Healthcare Medical Devices
Tandem Diabetes Care, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.0 billion, up 7.93% from fiscal 2024. In the quarter to June 2026, revenue grew 5.77%, EPS grew 60.3%, free cash flow fell 146.3% and total debt rose 94.9%, each against the same quarter a year earlier.
Follow TNDM
Tandem Diabetes Care, Inc. (TNDM) EV/Sales
As of 16 October 2026, Tandem Diabetes Care, Inc. (TNDM) trades at a EV/Sales of 1.2×. Over the past ten years it has ranged from 0.7× (June 2017) to 20.2× (September 2018); the current reading is higher than 18% of that period. That is below the Medical Devices industry median of 2.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 1.5× | (37.76%) |
| FY2024 | 2.4× | 6.87% |
| FY2023 | 2.2× | (29.64%) |
| FY2022 | 3.2× | (75.77%) |
| FY2021 | 13.0× | 16.82% |
| FY2020 | 11.1× | 21.30% |
| FY2019 | 9.2× | (4.96%) |
| FY2018 | 9.7× | 1,253.24% |
| FY2017 | 0.7× | (31.38%) |
| FY2016 | 1.0× | (74.55%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 1.1× | (12.70%) |
| Mar 2026 | 1.3× | (11.39%) |
| Dec 2025 | 1.5× | 82.93% |
| Sep 2025 | 0.8× | (35.07%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| LMRI Lumexa Imaging Holdings, Inc. compare | 1.0× |
| ENOV Enovis Corporation compare | 1.0× |
| TNDM Tandem Diabetes Care, Inc. | 1.2× |
| IART Integra LifeSciences Holdings Corporation compare | 1.6× |
| BVS Bioventus Inc. compare | 1.9× |
| PRCT PROCEPT BioRobotics Corporation compare | 2.5× |
| AORT Artivion, Inc. compare | 2.9× |
| CBLL CeriBell, Inc. compare | 8.3× |
| IRMD iRadimed Corporation compare | 12.4× |
| Medical Devices industry median | 2.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)